ReviewDrugs2021
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06195241 (The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Current Strategies in the Development of Nanoformulations to Enhance the Stability of Botox: A Systematic Review.AAPS PharmSciTech · 2025Pooled it
- Lifting the Mouth Corner: A Systematic Review of Techniques, Clinical Outcomes, and Patient Satisfaction.Aesthetic surgery journal · 2022Pooled it
- Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.Frontiers in neurology · 2022Pooled it
- Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.Neurology · 2024Trial
- Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.Aesthetic surgery journal · 2023Trial
- Botulinum Toxin A Myths, Evidence, and Global Media Narratives.Aesthetic plastic surgery · 2026Review
- Therapeutic botulinum toxin preparations: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage.Toxins · 2026Article
- Decades of Scientific Data and Global Media Reporting on Complications in Non-surgical Aesthetic Treatments for a Transparent Safety Profile: Kissing Snow White Awake.Aesthetic plastic surgery · 2025Article
- Trends, Hotspots, and Future Directions of Research on Pain in Dystonia: A Bibliometric Analysis.Brain and behavior · 2025Article
- Article
- Influence of the cosmetic use of botulinum toxin type a on temperature measurements using infrared thermography.Archives of dermatological research · 2025Article
- Peptide-Bound Aflibercept Eye Drops for Treatment of Neovascular Age-Related Macular Degeneration in Nonhuman Primates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Zinc in Dermatology: Exploring Its Emerging Role in Enhancing Botulinum Toxin Formulations and Clinical Efficacy.Current issues in molecular biology · 2024Review
- Article
- Review
- Immunogenicity of Botulinum Toxin Type A in Different Clinical and Cosmetic Treatment, a Literature Review.Life (Basel, Switzerland) · 2024Review
- Clinical effect of botulinum toxin type A combined with autologous fat grafting in patients with nasolabial fold depression.World journal of clinical cases · 2024Article
- Review
- Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.Toxins · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that maintain symptom relief between injections and reduce the frequency of re-treatment. DaxibotulinumtoxinA for Injection (DAXI) is a novel BoNTA product containing highly purified 150-kDa core neurotoxin and is the first to be formulated with a proprietary stabilizing excipient peptide (RTP004) instead of human serum albumin. The positively charged RTP004 has been shown to enhance binding of the neurotoxin to neuronal surfaces, which may enhance the likelihood of neurotoxin internalization. DAXI produces robust, extended efficacy across both aesthetic and therapeutic indications. In an extensive glabellar lines clinical program, DAXI showed a high degree of efficacy, a consistent median time to loss of none or mild glabellar line severity of 24 weeks, and median time until return to baseline of up to 28 weeks. In adults with cervical dystonia, DAXI at 125 U and 250 U significantly improved Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores, with a median duration of efficacy of 24 and 20 weeks, respectively, which compares favorably with the 12-14 weeks' duration reported for approved BoNTA products. Overall, DAXI was well tolerated, and the consistent extended duration of effect suggests that DAXI has the potential to improve the management of both aesthetic and therapeutic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.